Table 5.

Summary of the in vivo antineoplastic activities of TBK1 inhibitors

Compounds	Findings	References
AMX	Antitumor efficacy in mouse models of melanoma, glioblastoma, pro-B-cell leukemia, prostate cancer, and K-RAS-activated/CTLA4 blockade-resistant lung cancer. AMX and TMZ given in combination display synergism in human glioma cells in xenografts.	[100, 246, 249, 250, 252, 274]
Compound I	Antitumor capabilities when combined with PD-L1 blockade in mouse models of colorectal carcinoma.	[244, 270]
GSK8612	Inhibits HCC development in animal models by attenuating the production of immunosuppressive cytokines, consequently allowing enhanced infiltration of CD8+ T cells into the tumor.	[222]
MMB	Affords increased survival and decreased spleen size in mouse models of ovarian carcinoma and AML, respectively, and displays synergism with trametinib in suppressing PDA growth in animals.	[231, 275, 276]
200A	Anticancer activity in mouse models of squamous cell carcinoma.	[244, 270]